Search Results

You are looking at 111 - 120 of 2,881 items for :

  • Refine by Access: All x
Clear All
Full access

Associations Among Optimal Lung Cancer Treatment, Clinical Outcomes, and Health Care Utilization in Patients Who Underwent Comprehensive Genomic Profiling

Adam C. Powell, Elifnur Yay Donderici, Nicole J. Zhang, Shaun P. Forbes, Julie Wiedower, Amy C. McNeal, and Mark D. Hiatt

substantial, the real-world evidence is generally sparse on how using CGP in guiding treatment impacts outcomes and utilization. 9 CGP enables physicians to rapidly obtain a comprehensive view of a patient’s biomarkers. In contrast, sequential testing

Full access

Development of a Strategic Initiative at MD Anderson Cancer Center to Improve Outcomes in Immune-Related Adverse Events

Sarah E. Fayle, Nicolas L. Palaskas, Bilal A. Siddiqui, Jennifer L. McQuade, Jamie S. Lin, Sumit K. Subudhi, Anisha B. Patel, Robert R. Jenq, Amishi Y. Shah, Amy R. Spelman, Mianen Sun, Bettina H. Marble, and Yinghong Wang

Divisions of Internal Medicine and Cancer Medicine to standardize and expedite irAE diagnosis and management, disseminate best practices, and facilitate IOTOX research to improve patient outcomes. Rationale for IOTOX Initiative and Working Group

Full access

HSR19-112: Qualitative Development of a Patient-Reported Outcome Measure of Symptom Burden in Breast Cancer

Meagan S. Whisenant, Faith A. Strunk, Debasish Tripathy, and Loretta A. Williams

Background: The use of disease-specific patient-reported outcomes (PROs) is critical for facilitating individualized symptom monitoring and improving cancer patient outcomes. The MD Anderson Symptom Inventory (MDASI) is a PRO measure of symptom

Full access

Genetic Counseling Referral Rates in Long-Term Survivors of Triple-Negative Breast Cancer

Carlos H. Barcenas, Maryam N. Shafaee, Arup K. Sinha, Akshara Raghavendra, Babita Saigal, Rashmi K. Murthy, Ashley H. Woodson, and Banu Arun

primary outcome of interest was documentation of a formal recommendation from the medical provider for a genetic counseling session. Using the prospectively maintained Breast Cancer Database Management System housed in the Department of Breast Medical

Full access

Multidisciplinary Management of Locally Advanced Rectal Cancer: Neoadjuvant Approaches

Swaminathan Murugappan, William P. Harris, Christopher G. Willett, and Edward Lin

pathologic complete response (pCR). 11 HER2 expression was found in 27% of resected locally advanced rectal adenocarcinomas and may be associated with improved outcomes after multimodality therapy. 12 A key potential resistance mechanism in colorectal

Full access

Outcomes and Predictors of 28-Day Mortality in Patients With Hematologic Malignancies and Septic Shock Defined by Sepsis-3 Criteria

Nirmala K. Manjappachar, John A. Cuenca, Claudia M. Ramírez, Mike Hernandez, Peyton Martin, Maria P. Reyes, Alba J. Heatter, Cristina Gutierrez, Nisha Rathi, Charles L. Sprung, Kristen J. Price, and Joseph L. Nates

included small cohorts or were spread over long periods, leading to time bias. 5 , 15 , 16 In other studies, severe sepsis and septic shock are reported together. 5 , 14 This article reports on the short-term outcomes and the independent predictors of 28

Full access

Local Recurrence and Disease-Free Survival After Transanal Total Mesorectal Excision: Results From the International TaTME Registry

Sapho X. Roodbeen, Marta Penna, Susan van Dieren, Brendan Moran, Paris Tekkis, Pieter J. Tanis, Roel Hompes, and on behalf of the International TaTME Registry Collaborative

surgeon’s ability to achieve a meticulous cancer dissection. This may impair oncologic outcomes, particularly for locally advanced lower rectal cancer in male patients. 2 – 4 A laparoscopic rectal cancer operation results in short-term patient benefits

Full access

Biomarker Testing, Treatment, and Outcomes in Patients With Advanced/Metastatic Non–Small Cell Lung Cancer Using a Real-World Database

Naleen Raj Bhandari, Lisa M. Hess, Dan He, and Patrick Peterson

might not be treated in a way concordant with their test result and treatment guidelines, and a limited number of studies have investigated this in association with eventual survival outcomes. A study based on administrative claims data from 2010 to 2014

Full access

Representation and Outcomes of Older Adults in Practice-Changing Oncology Trials in the Era of Novel Therapies: A Guideline Appraisal

Ronald Chow, Daniel E. Lage, Grant R. Williams, Mina S. Sedrak, Joseph A. Greer, Jennifer S. Temel, and Ryan D. Nipp

that older adults represent less than one-third of cancer clinical trial participants. Moreover, according to a recent meta-analysis of >150 clinical trials, only between 40% and 70% of clinical trials reported on the outcomes of older adult subgroups

Full access

Race- and Sex-Based Disparities in the Therapy and Outcomes of Squamous Cell Carcinoma of the Anus

Nivedita Arora, Arjun Gupta, Hong Zhu, Alana Christie, Jeffrey J. Meyer, Saad A. Khan, and Muhammad S. Beg

(RT) considered first-line therapy, and salvage surgery used for resistant or recurrent disease. 8 Race and sex disparities related to access to care and outcomes have been studied for several malignancies, including pancreatic, breast, and lung